New test could prevent unneeded prostate cancer treatment

A new test from Genomic Health, the Oncotype DX Prostate Cancer Test, could reduce the number of men who undergo treatment for low-risk prostate cancer that would be better left untreated. The test rates the aggressiveness of a prostate biopsy based on an analysis of 17 genes and is more accurate than currently available tests, the developers say.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT